VRN101099, Brain Permeable HER2 Kinase Inhibitor, Shows the Anti-tumor Activity in Preclinical Models of HER2-positive Cancers

被引：0
|
作者：
Ko, Yikyung
Yoo, Jihye
Jung, Hong-Ryul
Lim, Hyerim
Lee, YeongDeok
Kim, Se Hyuk
Shin, Dong Guk
Cho, Serin
Heo, Myung Hoe
Kim, Haelee
Cho, Ha Yeon
Han, Ah Reum
Ko, Eunhwa
Choi, Hwan Geun
Kim, Deakwon
Kim, Sunghwan
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P1-11-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-11-03
引用
收藏
页数：2
相关论文
共 50 条
  • [1] VRN101396, a brain-permeable HER2 inhibitor, shows the anti-tumor activity in preclinical HER2-positive cancer models
    Jung, Hong-ryul
    Kim, Sunghwan
    Yoo, Jihye
    Park, Chan Mi
    Lee, Somi
    Lee, Hyoju
    Lee, Youngyi
    Park, Jinhee
    Seo, Kyungah
    Seo, Dong-Hyuk
    Ko, Eunhwa
    Son, Jung Beom
    Kim, Deakwon
    Choi, Hwan Geun
    Kim, Nam Doo
    CANCER RESEARCH, 2022, 82 (04)
  • [2] Anti-tumor effect of afatinib, an irreversible EGFR/HER2 dual inhibitor, in lung cancers harboring HER2 oncogene
    Suzawa, Ken
    Toyooka, Shinichi
    Sakaguchi, Masakiyo
    Ohtsuka, Tomoaki
    Watanabe, Mototsugu
    Hashida, Shinsuke
    Maki, Yuho
    Yamamoto, Hiromasa
    Soh, Junichi
    Asano, Hiroaki
    Tsukuda, Kazunori
    Miyoshi, Shinichiro
    CANCER RESEARCH, 2015, 75
  • [3] Response to anti-HER2 neoadjuvant chemotherapy in HER2-positive invasive breast cancers with different HER2 FISH patterns
    Lv, Hong
    Bai, Qian-Ming
    Li, Ming
    Cai, Meng-Yuan
    Zhou, Shu-Ling
    Liu, Yin
    Wang, Zhong-Hua
    Shui, Ruo-Hong
    Lu, Hong-Fen
    Xu, Xiao-Li
    Yu, Bao-Hua
    Tu, Xiao-Yu
    Bi, Rui
    Cheng, Yu-Fan
    Zhou, Xiao-Yan
    Shao, Zhi-Min
    Yang, Wen-Tao
    JOURNAL OF CLINICAL PATHOLOGY, 2024,
  • [4] Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells
    Kim, Hee-Jun
    Min, Ahrum
    Im, Seock-Ah
    Jang, Hyemin
    Lee, Kyung Hun
    Lau, Alan
    Lee, Miso
    Kim, Seongyeong
    Yang, Yaewon
    Kim, Jungeun
    Kim, Tae Yong
    Oh, Do-Youn
    Brown, Jeffrey
    O'Connor, Mark J.
    Bang, Yung-Jue
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (01) : 109 - 119
  • [5] Ebselen oxide and derivatives are new allosteric HER2 inhibitors for HER2-positive cancers
    Blasquez, Lucas
    Bouzinba-Segard, Haniaa
    Bourdoulous, Sandrine
    Faure, Camille
    MOLECULAR ONCOLOGY, 2023, 17 (10) : 1981 - 1999
  • [6] CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers
    Jiang-yan Cao
    Shuang Qi
    Hong Wu
    Ao-li Wang
    Qing-wang Liu
    Xi-xiang Li
    Bei-lei Wang
    Juan Ge
    Feng-ming Zou
    Cheng Chen
    Jun-jie Wang
    Chen Hu
    Jing Liu
    Wen-chao Wang
    Qing-song Liu
    Acta Pharmacologica Sinica, 2022, 43 : 2678 - 2686
  • [7] Allosteric Inhibition of HER2 by Moesin-Mimicking Compounds Targets HER2-Positive Cancers and Brain Metastases
    Faure, Camille
    Djerbi-Bouillie, Rym
    Domingot, Anais
    Bouzinba-Segard, Haniaa
    Taouji, Said
    Saidi, Yanis
    Bernard, Sandra
    Carallis, Floriane
    Rothe-Walther, Romy
    Lenormand, Jean-Luc
    Chevet, Eric
    Bourdoulous, Sandrine
    CANCER RESEARCH, 2021, 81 (21) : 5464 - 5476
  • [8] CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers
    Cao, Jiang-yan
    Qi, Shuang
    Wu, Hong
    Wang, Ao-li
    Liu, Qing-wang
    Li, Xi-xiang
    Wang, Bei-lei
    Ge, Juan
    Zou, Feng-ming
    Chen, Cheng
    Wang, Jun-jie
    Hu, Chen
    Liu, Jing
    Wang, Wen-chao
    Liu, Qing-song
    ACTA PHARMACOLOGICA SINICA, 2022, 43 (10) : 2678 - 2686
  • [9] Superior anti-tumor activity compared to T-DM1 in preclinical studies of targeted therapies for her2-positive cancers by a novel her2-ADC ZV0201
    Zhang, Hong
    Li, Zhaohui
    Zhu, Tong
    Cao, Sheldon
    Chen, Gang
    Miao, David
    CANCER RESEARCH, 2015, 75
  • [10] TAS0728, a covalent binding, selective inhibitor of HER2, shows antitumor activity in HER2+tumor models resistant to established anti-HER2 therapy
    Irie, H.
    Fujioka, Y.
    Ito, K.
    Oguchi, K.
    Osawa, H.
    Funabashi, K.
    Shimamura, T.
    Nakagawa, F.
    Kawabata, R.
    Nagase, H.
    Uchida, J.
    Okubo, S.
    Matsuo, K.
    Utsugi, T.
    Iwasawa, Y.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E124 - E125
12345